Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + famitinib + nab-paclitaxel in advanced solid tumors
CTR20220227Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, famitinib, paclitaxel, sponsored by Hengrui Therapeutics. Started Aug 2022; status: active.
02
Drugs
camrelizumabfamitinibpaclitaxel
Beyond the preview
Go deeper on CTR20220227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220227.